DNA vaccines targeting human papillomavirus-associated diseases: progresses in animal and clinical studies.
10.7774/cevr.2013.2.2.106
- Author:
Kyusun Torque HAN
1
;
Jeong Im SIN
Author Information
1. Department of Microbiology, School of Medicine, Kangwon National University, Chuncheon, Korea. jsin1964@hanmail.net
- Publication Type:Review
- Keywords:
Cervical cancer;
Cervical intraepithelial neoplasia;
DNA vaccines;
Electroporation;
Human papillomavirus
- MeSH:
Animals;
Cervical Intraepithelial Neoplasia;
DNA;
Electroporation;
Female;
Humans;
Incidence;
Proteins;
Uterine Cervical Neoplasms;
Vaccines;
Vaccines, DNA
- From:Clinical and Experimental Vaccine Research
2013;2(2):106-114
- CountryRepublic of Korea
- Language:English
-
Abstract:
Human papillomavirus (HPV) infection is a major cause of cervical cancer and its precancerous diseases. Cervical cancer is the second deadliest cancer killer among women worldwide. Moreover, HPV is also known to be a causative agent of oral, pharyngeal, anal and genital cancer. Recent application of HPV structural protein (L1)-targeted prophylactic vaccines (Gardasil(R) and Cervarix(R)) is expected to reduce the incidence of HPV infection and cervical cancer, and possibly other HPV-associated cancers. However, the benefit of the prophylactic vaccines for treating HPV-infected patients is unlikely, underscoring the importance of developing therapeutic vaccines against HPV infection. In this regard, numerous types of therapeutic vaccine approaches targeting the HPV regulatory proteins, E6 and E7, have been tested for their efficacy in animals and clinically. In this communication, we review HPV vaccine types, in particular DNA vaccines, their designs and delivery by electroporation and their immunologic and antitumor efficacy in animals and humans, along with the basics of HPV and its pathogenesis.
